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Current status of carotid artery stenting
Philip P. Goodney, MD,a Marc L. Schermerhorn, MD,b and Richard J. Powell, MD,a Lebanon, NH;
and Boston, Mass
This Clinical Update summarizes the results of larger case series, industry-sponsored registries, and randomized trials of
carotid artery stenting (CAS). In >20 case series that studied >24,000 patients undergoing CAS, 51% of patients were
symptomatic, most procedures (97%) resulted in successful stent deployment, and 30-day stroke rates varied from 1% to
8%, with a trend toward lower rates as experience and embolic protection device (EPD) use increased. In 12
industry-sponsored registries (none were published in peer-reviewed journals), 30-day stroke rates varied from 2% to 7%,
and 30-day combined adverse events, including stroke, death, and myocardial infarction, were 3% to 9%. More than 12
randomized trials comparing CAS and carotid endarterectomy (CEA) have been initiated since 1998. Results have varied
over time, depending on the population studied and the technology used. However, the largest and most recent results
of the completed SAPPHIRE trial in high-risk patients undergoing CAS with the use of EPDs demonstrated that CAS
is at least not inferior to CEA, with a 1-year combined adverse event rate of 12% for CAS and 20% for CEA (P  .05).
Other ongoing trials will address not only whether CAS could be superior to CEA in high-risk patients but also, more
importantly, whether CAS is beneficial in other subgroups, such as low-risk and asymptomatic patients. ( J Vasc Surg
2006;43:406-11.)Carotid artery stenting (CAS) is increasingly used in
place of carotid endarterectomy (CEA) even though few
randomized trials have directly compared these alterna-
tives. This is based in part on case series and industry-
sponsored registries, many of which have not yet been
published in peer-reviewed journals. This Clinical Up-
date reviews the status of CAS based on currently avail-
able data.
Case series. Since the advent of CAS in themid 1990s,
20 case series of at least 99 patients have been published,
reporting 24,000 patients (Table I). A weighted average
of these studies indicates that 51% of patients treated were
symptomatic and 97% received the planned stent. Inde-
pendent outcome evaluation by a neurologist was per-
formed in 64% of series.
After 2002, embolic protection devices (EPDs) were
widely used. In terms of outcomes, 30-day stroke rates
varied from 1% to 8%, but there was a trend toward lower
rates as experience increased with time and EPD use be-
came more widespread. Overall, the average 30-day stroke
rate was 3% across all studies, and the average combined
30-day rate of stroke, myocardial infarction, or death was
4%. These outcomes should be interpreted with caution,
however, because rates varied with year of procedure, EPD
use, neurologist examination, and patient characteristics.
Lastly, early restenosis rates appeared low (1% to 8%), albeit
only reported in half the studies.
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406Industry-sponsored registries. Results from 10
industry-sponsored trials of specific CAS systems have been
presented at national meetings, but none have yet been
published in a peer-reviewed journal. All of these registries,
except for the Acculink for Revascularization of Carotids in
High Risk Patients 1 (ARCHeR 1), routinely used EPDs.
(Table II). Stroke rates varied from 2% to 7% at 30 days, and
combined adverse outcome measures (stroke, death or
myocardial infarction) varied from 3% to 8% at 30 days. A
weighted average across these registries showed that 27% of
patients were symptomatic, 4% of patients experienced
periprocedural strokes, and combined adverse outcome
measures were 6% at 30 days.
Two registries have led to device approval by the US
Food and Drug Administration (FDA). The ARCHeR
registry was utilized by Guidant (Indianapolis, Ind) to
obtain United States Food and Drug Administration
(FDA) approval for the Accunet/Acculink system, and the
SECuRITY registry allowed Abbott (Abbott Park, Ill) to
obtain FDA approval for the Xact/Emboshield system.
These registries achieved low stroke rates for CAS. It is
important to note, however, that in the process of achieving
FDA approval, these results were compared with historical
controls of CEA in high-risk patients. For example, in
ARCHeR, the estimated stroke rate for high-risk patients
undergoing CEAwas 14.5%. Inmany centers of excellence,
combined adverse event rates after CEA in high-risk pa-
tients were much lower than that assumed by these regis-
tries, between 5% and 7%1,2 at 1 year.
Randomized trials. At least 12 trials directly compar-
ing CAS and CEA have been initiated (Table III). All
except Clopidogrel and Aspirin for Reduction of Emboli in
Symptomatic Carotid Stenosis (CARESS)3 were random-
ized controlled trials. All used independent neurologist
examinations to determine outcomes. Nearly all trials initi-
ome r
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CARESS assigned patients to CAS or CEA via “selection
criteria reflective of broad clinical practice.”3 CARESS
Table I. Case series of carotid artery stenting
Study author Year Patients/arteries (N) % sym
Dietrich22 1996 110/117 
Yadav23 1997 107/126 
Bergeron24 1999 97/99 
Henry25 2000 290/315 
Shawl26 2000 170/192 
Roubin27 2001 528/604 
Ahmadi28 2001 303/320 
Criado29 2002 132/135 
Guimaraens30 2002 164/192 
Al-Mubarek31 2002 162/164 
Kao32 2002 118/129 
Stankovic33 2002 100/102 
Kastrup34 2003 100/100 
Cremonesi35 2003 442/442 
Wholey36† 2003 11234/12392 
Cernetti37 2003 100/104 
Hobson38 2003 105/114 
Hobson5 2004 749/749 
Sztriha39 2004 245/260 
Henry40 2004 246/272 
Riemers41 2004 753/808 
Theiss21 2004 3270/3853 
Sganzerla42 2004 94/100 
Vos43 2005 509/509 
Yen44 2005 174/174 
Boseirs45† 2005 2712/2172 
Zahn46 2005 1734/1841 
Neuro MD, Independent neurologic evaluation by a neurologist; MI, myoc
This list represents all case series reported in peer-reviewed journals with gr
Stent type or EPD type reported as “multiple” if there was not a dominant
Stent type or EPD type reported as “variable” if stents or EPDs were not u
In some registries, individual patients experienced multiple adverse events.
*Combined complications included carotid dissection and intracranial hem
†Self reported multi-practitioner registry, not a case series.
‡Some results in this series represent 69 day results, not 30-day results.
Table II. Trials of carotid artery stenting
Name
Patients
(N)
Year
results
presented
Published in
peer-reviewed
journal
%
symptomat
SECuRITY47 305 2003 No Not reporte
ARCHER148 158 2004 No 25 
ARCHeR248 278 2004 No 24 
ARCHeR348 145 2004 No 21 
MOMA49 157 2005 No Not reporte
PRIAMUS49 416 2005 No 63 
PASCAL49 113 2005 No Not reporte
MAVERiC50 498 2004 No 24 
CREATE51 419 2004 No 17 
BEACH52 480 2005 No 25 
CABERNET53 433 2005 No 24
SHELTER54 — — No — 
Neuro MD, Independent neurologic evaluation by a neurologist; MI, myoc
Trials reported in chronological order of when results were presented. In s
combined rate is not always additive.achieved some of the lowest stroke and overall complica-tion rates reported across all trials for both CAS and CEA,
indicating the possibility that careful patient selection may
be one of the most important determinants of outcome for
atic % with stent Dominant stent % with EPD
99 Palmaz 0
100 Variable 0
97 Palmaz 0
99 Palmaz 52
99 Palmaz 0
98 Variable 0
93 Wallstent 0
98 SMART 0
99 Wallstent 90
99 Variable 95
100 Easy Wall 0
97 Variable 67
100 SMART 0
99 Wallstent 100
98 Variable 38
99 Variable 98
100 Wallstent 25
99 Acculink 88
99 Wallstent 0
100 Palmaz 99
100 Multiple 100
93 Multiple 64
100 Variable 100
98 Wallstent 30
100 Acculink 100
99 Multiple 85
100 Multiple 42
infarction; EPD, embolic protection device.
han or equal to 99 patients or arteries.
sed.
each patient in the series.
fore combined rate is not always additive.
e.
Stent
Embolic
protection
device
30-day
stroke
%
30-day
death
%
30-day
MI
%
30-day
combined
%
act Emboshield 6.9 0.3 0 7.2
cculink None 4.4 2.5 2.5 7.6
cculink Accunet 2.2 5.8 2.9 8.6
cculink Accunet 1.4 6.2 0.7 8.3
ariable MOMA 5.7 — 0 5.7
ariable MOMA 4.2 0.4 — 4.6
xponent Variable — — — 8.0
xponent Guardwire 2.0 2.0 1.2 5.1
rotégé Spider 3.3 1.0 0.5 4.8
allstent Filterwire 4.2 1.5 0.8 5.8
exStent Filterwire 3.4 0.5 0.2 3.8
allstent Guardwire Plus — — — —
infarction.
egistries, individual patients experienced multiple adverse events; thereforeptom
28 
59 
44 
42 
61 
48 
38 
40 
92 
48 
75 
37 
63 
57 
53 
23 
39 
31 
53 
64 
26 
56 
34 
33 
36 
41 
55 
ardial
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outcomes, the Stenting and Angioplasty with Protection in
Patients at High Risk for Endarterectomy (SAPPHIRE)
trial is most widely cited because it reported 2-year results
with uniform usage of EPDs. In this trial, 334 patients who
were considered high risk for CEA were randomized to
CEA or CAS.4 High-risk was defined as having at least one
of the following risk factors: clinically significant heart
disease, severe pulmonary disease, contralateral carotid oc-
clusion, contralateral laryngeal nerve palsy, previous radical
neck surgery or radiation therapy to the neck, recurrent
stenosis after endarterectomy, or age 80 years. The com-
bined 30-day end point of stroke, death, or myocardial
infarction was 4.4% for CAS vs 9.8% for CEA (P .06). At
1 year, this combined end point was 12% for CAS vs 20% for
CEA (P  .05). The authors concluded that carotid stent-
ing with embolic protection is not inferior to CEA in
high-risk patients. This trial was terminated early when
recruitment slowed; it is likely that a larger trial would have
shown CAS to be superior to CEA in high-risk patients as
defined in this study.
Multiple ongoing randomized controlled trials are fo-
cused on both high- and lower-risk patients, including
Carotid Revascularization Endarterectomy Versus Stenting
Trial (CREST),5 International Carotid Stenting Study
(ICSS),6 Stent-Supported Percutaneous Angioplasty of the
Carotid Artery versus Endarterectomy (SPACE)7, Endar-
terectomy Versus Angioplasty in Patients with Severe
Symptomatic Carotid Stenosis (EVA-3S),8 and Asymp-
Table I. Continued.
Dominant EPD Neuro MD 30-day stroke % 30-day death %
None No 6.4 0.9
None Yes 7.0 0.9
None Yes 5.0 0.0
Percusurge Yes 4.2 0.3
None Yes 2.9 0.0
None No 5.8 0.0
None Yes 7.8 0.6
None No 3.0 0
Variable No 1.0 1.9
Neuroshield Yes 1.0 1.0
None No 2.4 2
Neuroshield Yes 7.0 0.0
None No 7.0 1.0
Angioguard Yes 1.1 0.0
Variable No 4.0 0.8
Percusurge Yes 3.0 1.0
Accunet Yes 1.0 2.0
Accunet Yes 4.0 0.8
None Yes 3.1 0.4
Percusurge No 1.9 0.4
Multiple Yes 5.6 0.1
Multiple Yes 2.5‡ 0.6‡
Variable Yes 5.0 0.0
Filterwire Yes 3.7 1.0
Angioguard Yes 1.7 1.7
Multiple No
Emboshield No 3.0 0.8tomatic Subjects with Significant Extracranial Carotid Oc-clusive Disease Trial” (ACT I).9 CREST is a randomized
trial comparing CEA and CAS in low-risk patients with
both symptomatic stenoses 50% and asymptomatic ste-
noses80%. As part of the lead-in phase to this study, 749
patients (31% symptomatic) underwent CAS. Thirty-day
stroke-death rates increased with age such that there was a
12.1% 30-day stroke-death rate for patients80 years old
compared with 3.2% for patients80 years of age. ICSS,
SPACE, and EVA-3S are randomizing symptomatic pa-
tients, while ACT I is randomizing asymptomatic pa-
tients.
Embolic protection devices. Most current data sug-
gest that CAS can be performed with acceptable stroke
rates only with the use of EPDs.10 The first use of an EPD
in CAS was described in France in the 1990s.11 Since then,
many different devices have been developed (Table IV).
Most of these are wire-based filters that trap embolic debris.
Currently, the Guidant ACCUNET Filterwire12 and the
Abbott Emboshield13 are the only FDA-approved EPDs
for use with CAS in the United States.14 In addition to
filters, distal internal carotid artery balloon occlusion with
subsequent aspiration can be used for embolic protection
(GuardWire, Medtronic, Minneapolis, Minn15) as well as
flow blockage in the internal carotid artery with common
and external carotid balloon occlusion (MOMA, Invatec,
Roncadelle, Italy16), or flow reversal in the internal carotid
artery with the Parodi Anti-Emboli System (W. L. Gore &
Associates, Flagstaff, Ariz17). Different devices may have
advantages in selected patients based on device size, lesion
ay MI % 30-day combined % Restenosis % Follow-up (months)
— 10.9 3.4 3
— 7.9 4.9 6
0.0 5.0 3.0 13
— — 4.7 13
0.0 0.0 2.0 19
0.0 7.4 3.1 36
0.0 8.4 8.0 12
0.0 3.0 3.0 16
— 3.0 4.1 12
0.0 2% — —
— 2.4 3.1 16
0.0 7.0 3.4 12
0.0 8.0 — —
0.0 3.4* 30 days
— 4.8 2.4 36
1.0 5% 1.8 24
1.0 3.0 3.8 26
— 4.4. — —
0.0 3.5 — —
0.0 2.3 0.5 23
0.0 5.7 — —
— 2.8^
0.0 5.0 — —
0 4.7 — —
— 3.4 — —
1.2 3.4 72
— 3.8 — —30-dcharacteristics, internal carotid artery tortuosity, and other
d clini
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studies, so that EPD selection is currently based on individ-
ual practitioner experience.
Approval and reimbursement for stents and EPDs
in the United States. The FDA approved the Guidant
Acculink/Accunet CAS system in August 200414 and the
Abbott Xact/Emboshield CAS system in September 2005.18
These devices were approved for limited application, spe-
cifically for symptomatic patients with 50% internal ca-
rotid artery stenosis or asymptomatic patients with 80%
internal carotid artery stenosis who are considered to be at
high risk for CEA. In this regard, patients can be at high
physiologic risk for CEA because of risk factors such as
severe coronary artery or pulmonary disease, end-stage
renal disease, and uncontrolled diabetes mellitus.14 Pa-
Table III. Randomized trials of carotid artery stenting
Name
CAS
patients
CEA
patients
Year
results
presented
P
p
Naylor et al 55 7 10 1998 
Alberts et al56 107 112 2001 
Brooks et al57 52 52 2001 
Brooks et al58 43 42 2004 
CAVATAS:20 251 253 2001 
CARESS3†‡ 254 143 2003 
SAPPHIRE4 167 167 2004 
EVAS-3S8, 59*† 150 150 2004 
CREST5*† 1250 1250 — 
ICSS6*† 750 750 — 
CAVATAS II60*† 233 233 — 
ACT I9*† 750 750 — 
SPACE7†* 430 430 — 
CAS, Carotid artery stenting, CEA, carotid endarterectomy; Neuro MD, ind
embolic protection device.
Stent type or EPD type reported as “multiple” if there was not a dominant
*Trial currently ongoing.
†Number of patients listed represents the number planned for enrollment.
‡Not randomized. Patients assigned via “selection criteria reflective of broa
§CAS stroke rate based on first 80 patients in CAS arm.
Table IV. Embolic protection devices commonly utilized
Device Manufacturer
Filterwire Boston Scientific Wire-depl
Interceptor Medtronic Wire-depl
Angioguard Cordis Wire-depl
Spider EV3 Wire-depl
Rubicon Rubicon Wire-depl
Accunet Guidant Wire-depl
Emboshield Abbott Wire deplo
Guardwire Medtronic Occlusion
aspiratio
MOMA Invatec Common
balloon
Parodi Anti-Embolic System Gore Common
balloon
reversaltients can also be at high anatomic risk for CEA because ofrisk factors such as contralateral internal carotid artery
occlusion, radiation treatment to the neck, distal internal
carotid artery location, spinal immobility, tracheostomy
stoma, or contralateral laryngeal nerve paralysis.14 Ongo-
ing randomized trials will determine effectiveness of CAS in
lower-risk populations, but until these results are available,
precise definitions of high-risk patients appropriate for CAS
are being determined by these broad guidelines combined
with individual practitioner experience.
Currently CAS is reimbursed by the Center for Medi-
care and Medicaid Services (CMS) only for FDA-approved
devices. In addition, CMS will reimburse only for treat-
ment of symptomatic, high-risk patients with70% steno-
sis in CMS-approved centers. Additionally, in approved
clinical trials, CMS will reimburse for symptomatic, high-
ed in a
viewed
nal? Dominant stent Dominant EPD
Neuro
MD
es None None Yes
es Wallstent None Yes
es Variable Variable Yes
es Wallstent/Dynalink None Yes
es Variable None Yes
es Wallstent Guardwire Plus Yes
es Smart/Precise Angioguard Yes
es Multiple Multiple Yes
 Acculink Accunet Yes
 Multiple Multiple Yes
 Multiple Multiple Yes
 Xact Emboshield Yes
 Acculink Accunet Yes
ent neurologic evaluation by neurologist; MI, myocardial infarction; EPD,
sed.
cal practice.”
rotid artery stenting
anism Trials/reports Profile (Fr)
basket with filter BEACH52, CABERNET53 3.2
basket with filter MAVERiC50 2.9
basket with filter SAPPHIRE4 3.2-3.7
basket with filter CREATE51 2.9
basket with filter RULE-Carotid61 2.1-2.7
basket with filter ARCHER48, SPACE7,
CREST5
3.5-3.7
basket with filter SECuRITY47 2.9-3.3
on and
heter
CARESS, SHELTER54 2.8
id flow blockage
m
Coppi et al62, Reimers63 N/A
id flow blockage
m with flow
Parodi et al64 N/Aublish
eer-re
jour
Y
Y
Y
Y
Y
Y
Y
Y
—
—
—
—
—
epend
type uin ca
Mech
oyed 
oyed 
oyed 
oyed 
oyed 
oyed 
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n cat
carot
syste
carot
systerisk patients with 50% to 69% stenosis and asymptomatic
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must be entered into a registry to track outcome for poten-
tial CMS review. In this regard, the Society for Vascular
Surgery has established a registry that meets these require-
ments and which should provide useful future data.19
Variation in reporting. Evaluation of current case se-
ries, industry-sponsored registries, and randomized trials re-
veals variation in study design and outcome measurement:
First, duration of follow-up varies from 30 days in the
Carotid and Vertebral Artery Transluminal Angioplasty
Study-I (CAVATAS-I),20 1 year in SAPPHIRE,4 and up to
2 years in Prospective Registry of Carotid Angioplasty and
Stenting (Pro-CAS),21 albeit some of this variation simply
represents differences in the current stage of result report-
ing. Although inherent differences in follow-up duration
are likely, it becomes difficult to compare outcomes across
trials with such distinct differences.
Second, outcome event measurement has not been
standardized. For example, SAPPHIRE classified strokes as
minor and major, according to the National Institutes of
Health Stroke Scale. CAVATAS, meanwhile, divided major
adverse outcomes into “disabling stroke or death” or
“stroke lasting more than 7 days.”
Third, primary endpoints have also varied. ARCHeR 1
and 2 considered all deaths, strokes, and myocardial infarc-
tions at 30 days and ipsilateral strokes until 1 year as primary
end points, but ARCHeR 3 reported only all deaths,
strokes, and myocardial infarctions at 30 days. Reporting
standards need to be established to allow comparison and
interpretation across studies.
CONCLUSIONS
As with other minimally invasive surgical procedures,
CAS has developed rapidly over the last decade. Although
equivalency with CEA has been established in high-risk
patients, the effectiveness of CAS in lower-risk patients is
not yet established. However, the choice of CEA vs CAS in
individual patients is currently based more on individual
Table III. Continued.
30-day stroke % 30-day dea
Follow-up CAS CEA CAS
30 days 71 0
1 year 12.1 3.6
30 days 0 0.0 0
2 years 0 0 0
30 days 8.0 8.0 3.0
30 days 2.1 3.6 0.0
2 years 3.6 3.1 1.2
4 years 8.6§
4 years — — —
30 days — — —
5 years — — —
1 year — — —
30 days — — —practitioner experience than on clear evidence-derivedguidelines. N onetheless, the popularity of less invasive
therapy combined with marketing of new CAS systems
has increased the utilization of CAS. Ongoing random-
ized trials will help determine optimal carotid revascular-
ization strategies in the future.
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